Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

893
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
893
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

695
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
695
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

906
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
906
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

944
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
944
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing ASHP and PQA Frameworks for Identifying Medication Therapy Problems in Older Adults with COPD Discharged to Home Health Care: A Cross-Sectional Study.

The Senior care pharmacist·2026
Same author

Experience using a state board of pharmacy adequate staffing form: A descriptive report.

Currents in pharmacy teaching & learning·2025
Same author

Montelukast deprescribing in outpatient specialty clinics: A single center cross-sectional study.

Exploratory research in clinical and social pharmacy·2024
Same author

Hospitalization and Health Resource Utilization in Emergency Department Cases of Diabetic Foot Infections in the U.S. from 2012 to 2021: A Nationally Representative Analysis.

Journal of clinical medicine·2024
Same author

To the Editor and Readership of Alzheimer Disease and Associated Disorders.

Alzheimer disease and associated disorders·2023
Same author

The Medication Possession Ratio as a Predictor of Longitudinal HIV-1 Viral Suppression.

The Annals of pharmacotherapy·2023

Related Experiment Video

Updated: Mar 19, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.6K

Propofol-associated QTc prolongation.

Michael J Scalese1, Holly R Herring2, R Chris Rathbun3

  • 1Auburn University Assistant Clinical Professor, Department of Pharmacy Practice Auburn University Harrison School of Pharmacy 650 Clinic Drive, Rm 2100 Mobile, AL 36688.

Therapeutic Advances in Drug Safety
|June 15, 2016
PubMed
Summary
This summary is machine-generated.

Propofol infusion in intensive care unit (ICU) patients may prolong the corrected QT interval (QTc). This association was linked to higher baseline QTc and amiodarone use in a historical cohort study.

Keywords:
QTc prolongationintensive carepropofolsafety

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.6K

Related Experiment Videos

Last Updated: Mar 19, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.6K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.3K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.6K

Area of Science:

  • Cardiology
  • Pharmacology
  • Intensive Care Medicine

Background:

  • Propofol is a widely used sedative in ICUs.
  • Concerns exist regarding propofol's potential to prolong the corrected QT interval (QTc).
  • Limited empirical data exists on this association in ICU settings.

Purpose of the Study:

  • To investigate the relationship between propofol infusion and QTc prolongation.
  • To analyze QTc interval changes in a historical cohort of ICU patients receiving propofol.

Main Methods:

  • Single-center, observational, pre-post cohort study.
  • Analysis of medical records from 96 adult cardiovascular disease patients receiving propofol for ≥3 hours.
  • Multivariable regression to assess QTc prolongation, controlling for clinical factors.

Main Results:

  • Mean QTc interval prolongation of 30.4 ± 55.5 ms observed during propofol infusion (p < 0.001).
  • 43.8% of patients showed QTc ≥ 500 ms.
  • Prolongation associated with higher baseline QTc and amiodarone use; inversely associated with weight.

Conclusions:

  • Propofol infusion in ICU patients is associated with QTc prolongation.
  • Higher baseline QTc and concurrent amiodarone use are key factors.
  • Further research needed to establish clinical significance and causality.